Description: Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a portfolio of late-stage drugs for orphan diseases. It offers Sarasar, which is used for the treatment of hepatitis delta; Exendin that is used for the treatment of hypoglycemia; and Bestatin, which is used for the treatment of pulmonary arterial hypertension and lymphedema. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is based in Palo Alto, California.
Home Page: www.eigerbio.com
EIGR Technical Analysis
2155 Park Boulevard
Palo Alto,
CA
94306
United States
Phone:
650 272 6138
Officers
| Name | Title |
|---|---|
| Mr. David A. Cory M.B.A., MBA, R.Ph, R.Ph. | Bus. Founder, Pres, CEO & Director |
| Dr. Jeffrey S. Glenn M.D., Ph.D. | Scientific Founder & Independent Director |
| Mr. Sriram Ryali M.B.A. | Chief Financial Officer |
| Mr. Eldon C. Mayer III, M.B.A. | Exec. VP & Chief Commercial Officer |
| Mr. Christopher A. Kurtz | Chief Technical Officer |
| Mr. Erik Atkisson | Gen. Counsel, Corp. Sec. & Chief Compliance Officer |
| Dr. Ingrid C. Choong | Sr. VP of Clinical Devel. |
| Dr. Stephana E. Patton J.D., Ph.D. | Consultant |
| Mr. Rich Franco M.B.A. | Sr. VP of Regulatory Affairs |
| Dr. Colin Hislop M.D. | Sr. VP of Clinical & Devel. Operations |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7598 |
| Price-to-Sales TTM: | 3.5514 |
| IPO Date: | 2014-01-30 |
| Fiscal Year End: | December |
| Full Time Employees: | 54 |